Ren
.
- Messages
- 385
For general info...
This is a somewhat dated article that I happened upon when looking for info on NIH's grant-review process, includng bias/corruption. Insel (see below) has been written about recently on PR for his advocated break with DSM.
I. "NIH, NIMH Aids Another Corrupt Doctor" (2010)
II. CDC: "Childhood Adversity as a Risk Factor for Adult CFS" (2011)
I. "NIH, NIMH Aids Another Corrupt Doctor" (12 June 2010).
From The Office of Medical and Scientific Justice * (Anyone familiar with this source??)
"A yearlong effort by the National Institutes of Health to toughen its policies against financial conflicts of interest was led by an administrator [Thomas Insel] who quietly helped one of the most prominent transgressors [Charles B. Nemeroff] get hired by the University of Miami after a decade of undisclosed corporate payments led to his departure from Emory University..."
"The administrator, Thomas R. Insel, director of the National Institute of Mental Health, also encouraged the researcher, Charles B. Nemeroff, to apply for new NIH grants, even though Emory had agreed on its own to restrict Dr. Nemeroff from NIH grant eligibility for two years. The NIH also allowed Dr. Nemeroff uninterrupted eligibility to serve on NIH advisory panels that help decide who receives NIH grant money..."
"The actions by Dr. Insel, during a period of heavy Congressional pressure on the NIH to institute reforms, raise new questions about the NIH’s stated commitment to attacking the problem of financial conflicts of interest in taxpayer-financed medical research..."
"Dr. Insel has declined months of requests from The Chronicle for an interview to discuss the matter, including his relationship with Dr. Nemeroff. The NIH’s director, Francis S. Collins, was not available for comment... Dr. Nemeroff also declined to be interviewed..."
"Dr. Nemeroff is one of several high-profile doctors found to have given speeches or written articles in medical journals extolling drugs or products made by companies that had paid them money or stock benefits that they did not report to their universities..."
"In the case of Dr. Nemeroff, a pattern of accepting undisclosed corporate payments goes back at least a decade. In 2003, the journal Nature toughened its policies for author disclosures after Dr. Nemeroff used an article in Nature Neuroscience to praise treatments for depression in which he had an unreported financial interest. In 2004, Emory issued a report citing him for multiple "serious" violations of its conflict-of-interest policies for protecting patients.
He quit as editor of the journal Neuropsychopharmacology in 2006 after he was reported to have endorsed an implantable device for treating depression without disclosing payments from its manufacturer. And he finally left Emory last year [2009], after U.S. Senate investigators found he received $2.8-million from GlaxoSmithKline and other pharmaceutical companies between 2000 and 2007 and failed to disclose at least $1.2-million of it..."
"A year later, Dr. Nemeroff assumed his new position, professor and chairman of the department of psychiatry and behavioral sciences, at the University of Miami. His new supervisor, Dr. Goldschmidt, said he was pleased to hear from Dr. Insel that Dr. Nemeroff not only could begin applying for NIH grants as soon as he arrived in Coral Gables, but that he could also continue to serve on the NIH’s expert panels that help decide on which grant applications win federal financing..."
"It was the latest benefit for both sides [Insel + Nemeroff] to a relationship that Dr. Nemeroff had cultivated for at least 16 years..."
"Dr. Nemeroff began offering help to the now-director of the NIMH [Insel] in 1994, when Dr. Insel was facing the nonrenewal of his research job at the NIH, Mr. Carroll said, bringing him to Emory to serve as a professor of psychiatry and director of the Yerkes Regional Primate Research Center. Dr. Nemeroff also led a lobbying effort that helped ensure Dr. Insel’s appointment in 2002 as NIMH director, Mr. Carroll said.
Mr. Carroll, who supervised Dr. Nemeroff for six years at Duke, describes the career assistance for Dr. Insel as part of a strategy in which Dr. Nemeroff would "put people in debt to him, and then call in the chips later..."
"The NIH’s regulatory review process, led by Dr. Insel and Sally J. Rockey [an entomologist??!**], the NIH’s acting deputy director for extramural research..."
*http://www.omsj.org/corruption/nih-nimh-aids-another-corrupt-doctor
**http://womeninscience.nih.gov/pdf/NIH_WomenInScience_Sec1.pdf
II. CDC: "Childhood Adversity as a Risk Factor for Adult CFS" (2011)*
Note - Nemeroff is a co-author in two (2008) references.
*http://www.cdc.gov/cfs/news/features/childhood_adversity.html
This is a somewhat dated article that I happened upon when looking for info on NIH's grant-review process, includng bias/corruption. Insel (see below) has been written about recently on PR for his advocated break with DSM.
I. "NIH, NIMH Aids Another Corrupt Doctor" (2010)
II. CDC: "Childhood Adversity as a Risk Factor for Adult CFS" (2011)
I. "NIH, NIMH Aids Another Corrupt Doctor" (12 June 2010).
From The Office of Medical and Scientific Justice * (Anyone familiar with this source??)
"A yearlong effort by the National Institutes of Health to toughen its policies against financial conflicts of interest was led by an administrator [Thomas Insel] who quietly helped one of the most prominent transgressors [Charles B. Nemeroff] get hired by the University of Miami after a decade of undisclosed corporate payments led to his departure from Emory University..."
"The administrator, Thomas R. Insel, director of the National Institute of Mental Health, also encouraged the researcher, Charles B. Nemeroff, to apply for new NIH grants, even though Emory had agreed on its own to restrict Dr. Nemeroff from NIH grant eligibility for two years. The NIH also allowed Dr. Nemeroff uninterrupted eligibility to serve on NIH advisory panels that help decide who receives NIH grant money..."
"The actions by Dr. Insel, during a period of heavy Congressional pressure on the NIH to institute reforms, raise new questions about the NIH’s stated commitment to attacking the problem of financial conflicts of interest in taxpayer-financed medical research..."
"Dr. Insel has declined months of requests from The Chronicle for an interview to discuss the matter, including his relationship with Dr. Nemeroff. The NIH’s director, Francis S. Collins, was not available for comment... Dr. Nemeroff also declined to be interviewed..."
"Dr. Nemeroff is one of several high-profile doctors found to have given speeches or written articles in medical journals extolling drugs or products made by companies that had paid them money or stock benefits that they did not report to their universities..."
"In the case of Dr. Nemeroff, a pattern of accepting undisclosed corporate payments goes back at least a decade. In 2003, the journal Nature toughened its policies for author disclosures after Dr. Nemeroff used an article in Nature Neuroscience to praise treatments for depression in which he had an unreported financial interest. In 2004, Emory issued a report citing him for multiple "serious" violations of its conflict-of-interest policies for protecting patients.
He quit as editor of the journal Neuropsychopharmacology in 2006 after he was reported to have endorsed an implantable device for treating depression without disclosing payments from its manufacturer. And he finally left Emory last year [2009], after U.S. Senate investigators found he received $2.8-million from GlaxoSmithKline and other pharmaceutical companies between 2000 and 2007 and failed to disclose at least $1.2-million of it..."
"A year later, Dr. Nemeroff assumed his new position, professor and chairman of the department of psychiatry and behavioral sciences, at the University of Miami. His new supervisor, Dr. Goldschmidt, said he was pleased to hear from Dr. Insel that Dr. Nemeroff not only could begin applying for NIH grants as soon as he arrived in Coral Gables, but that he could also continue to serve on the NIH’s expert panels that help decide on which grant applications win federal financing..."
"It was the latest benefit for both sides [Insel + Nemeroff] to a relationship that Dr. Nemeroff had cultivated for at least 16 years..."
"Dr. Nemeroff began offering help to the now-director of the NIMH [Insel] in 1994, when Dr. Insel was facing the nonrenewal of his research job at the NIH, Mr. Carroll said, bringing him to Emory to serve as a professor of psychiatry and director of the Yerkes Regional Primate Research Center. Dr. Nemeroff also led a lobbying effort that helped ensure Dr. Insel’s appointment in 2002 as NIMH director, Mr. Carroll said.
Mr. Carroll, who supervised Dr. Nemeroff for six years at Duke, describes the career assistance for Dr. Insel as part of a strategy in which Dr. Nemeroff would "put people in debt to him, and then call in the chips later..."
"The NIH’s regulatory review process, led by Dr. Insel and Sally J. Rockey [an entomologist??!**], the NIH’s acting deputy director for extramural research..."
*http://www.omsj.org/corruption/nih-nimh-aids-another-corrupt-doctor
**http://womeninscience.nih.gov/pdf/NIH_WomenInScience_Sec1.pdf
II. CDC: "Childhood Adversity as a Risk Factor for Adult CFS" (2011)*
Note - Nemeroff is a co-author in two (2008) references.
*http://www.cdc.gov/cfs/news/features/childhood_adversity.html
